CM Hospitalar S/A (VVEO3) Fair Value & Analysis

Healthcare · BR · Market cap R$180M

A solid business, but screening 34% overvalued on our models.

What matters now

• The model range is unusually wide (R$0.1935 to R$0.6309). The outcome hinges heavily on assumptions, so read the point estimate with caution.
• Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 14, 2026.

How to read this chart

60‑month range R$0.5600 – R$25.31 · fair‑value band R$0.1935 – R$0.6309 · the R$0.6300 price screens above the R$0.4169 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 14, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

CM Hospitalar S/A (VVEO3) currently trades at R$0.6300, while our model-based Fair Value estimate is R$0.4169, implying the stock looks roughly 33.8% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, CM Hospitalar S/A generated revenue of R$11.6B at a net margin of 0.2%. Revenue grew 1.7% year over year. It earns a return on equity of 1.1%. Net debt stands at R$2.9B. Fundamentals as of Aug 14, 2026

Our scenario range runs from R$0.1935 (bear case) to R$0.6309 (bull case); at R$0.6300, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 66% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -7% fair-value upside, at -34%, VVEO3 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (R$15.82) versus Growth DCF (R$0.9800). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

CM Hospitalar S/A engages in the distribution of hospital materials, medicines, and nutrition products in Brazil. The company offers material products for cardiac, surgical, urinary, diagnosis, sterilization, wound management, hygiene and protection, infusion, clinical nutrition, orthopedic, and respiratory; and medications, such as painkillers, …

Full company description

CM Hospitalar S/A engages in the distribution of hospital materials, medicines, and nutrition products in Brazil. The company offers material products for cardiac, surgical, urinary, diagnosis, sterilization, wound management, hygiene and protection, infusion, clinical nutrition, orthopedic, and respiratory; and medications, such as painkillers, anesthetics, anti-allergy, antibiotics, antiemetics, antifungals, anti-inflammatory, special control, several, and oncology. It also provides materials for respiratory assistance, therapy, anti-inflammatories, anti-tnf, antacid, antiandrogens, antianemics, anti-asthmatics, antibiotics, anticoagulant, anticonvulsant, monoclonal antibody, anti-growth, antidepressants, antidiabetic drug, antidiuretics, antidote, antiemetics and antinauseants, anti-migraine, antiepileptics, antiestrogens, antifibrinolytics, antiflatulents, antifungals, antihemorrhagic drug, antimicrobial, antineoplastics, antiparathyroid, antiparkinsonian, antipsychotics, systemic antipsoriasis, antirheumatic drugs, anti-varicose, antivirals, beta-blockers, carbohydrate, cycloplegic, contraceptives, contrast, special control, corticosteroids, topical debriding agent, diuretics, several, electrolyte, pancreatic enzyme, erythropoietins, uterine stimulant, cardiac stimulators, growth factor, granulocyte colony stimulating factor, gastroprokinetics, systemic hemostatics, heparins, hepatoprotective and lipotropic agents, hormone, adenohypophyseal hormones, growth hormones, immunoglobulins, immunosuppressants, labor induction drugs, proton pump inhibitor, phosphodiesterase and bone resorption inhibitor, platelet aggregation inhibitors, adenosine diphosphate receptor antagonists, proton pump inhibitors, interleukin inhibitors, subtilisin/kexin type 9 proprotein convertase inhibitors, calcium reabsorption inhibitors, materials, medications, nutrition, therapy, orthopedic therapy. CM Hospitalar S/A was incorporated in 2010 and is headquartered in São Paulo, Brazil.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

CM Hospitalar S/A reported revenue of R$11.6B in FY2025 versus R$6.2B in FY2021, a compound +16.8%/yr. Reported net income was R$18.2M in FY2025, compounding −53.6%/yr from FY2021.

VVEO3 screens 34% overvalued. Compare with McKesson Corporation →

Peer Group

Medical Distribution · 77 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Distribution median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 14, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.